<DOC>
	<DOCNO>NCT00080509</DOCNO>
	<brief_summary>The purpose study determine whether potential drug know KOS-862 `` Epothilone D '' effect 2nd line treatment non-small cell lung cancer ( NSCLC ) patient fail one prior platinum-containing chemotherapy regimen .</brief_summary>
	<brief_title>Effectiveness KOS-862 Treatment Lung Cancer</brief_title>
	<detailed_description>To determine antitumor activity , base confirm objective response rate , KOS-862 , administer intravenously weekly 3 week every 4 week , patient non-small cell lung cancer ( NSCLC ) whose disease progress follow initial chemotherapy advance metastatic disease .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>At least 18 year age Measurable disease One previous treatment platinum base drug cisplatin carboplatin At least 3 week since last surgery/radiation/chemotherapy Brain metastasis Changes rhythm heart consider significant determine ECG trace</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>